Yi, Jingjie http://orcid.org/0000-0001-9908-0087
Li, Huan
Chu, Bo http://orcid.org/0000-0001-9754-2743
Kon, Ning
Hu, Xiaoping
Hu, Jianping
Xiong, Yan
Kaniskan, H. Umit
Jin, Jian http://orcid.org/0000-0002-2387-3862
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA253059, RO1CA258390, R01CA254970)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | National Institutes of Health (1S10OD025132, 1S10OD028504)
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 6 February 2023
Revised: 28 April 2023
Accepted: 18 May 2023
First Online: 8 June 2023
Competing interests
: JJ is a cofounder and equity shareholder in Cullgen, Inc., a scientific cofounder and scientific advisory board member of Onsero Therapeutics, Inc., and a consultant for Cullgen, Inc., EpiCypher, Inc., Accent Therapeutics, Inc, and Tavotek Biotherapeutics, Inc. The Jin laboratory received research funds from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. The other authors declare that they have no competing financial interests.
: All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at Columbia University under the supervision of the Institute of Comparative Medicine.